

CERTIFICATE OF MAILING

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450 ON MAY 25, 2007.

trudy 5. Halber

Signature of person depositing this document

5-25-2007 DATE

Attorney Docket No. P32976

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Daines et al.

May 25, 2007

Serial No.:

10/502,233

Group Art Unit No.: 1625

Filed:

July 22, 2004

Examiner: Z. Davis

For:

AMINOPIPERIDINE DERIVATIVES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)(2)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein, however, should not be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2).

Some of the documents listed in the attached form PTO-1449 are not in the English language. Listed below are English language family members for the noted non-English publications:

Non-English language document	English language family member
WO01/25227	US 6,403,610, see also EP1218370B1
	English language claims
WO02/040474	US 6,603,005; US 6,903,217
WO02/072572	US 6,602,884; US 6,815,547
WO04/024712	US 2004/0087619A1

Serial No.: 10/502,233

WO04/024713	US 6,841,562
WO04/035569A2	US 2006/0040949A1
BE772190A1	GB1345872
EP0374095A2	CA2004986A1
EP0532456A1, B1	US 5,310,743; US 5,541,195; US
	5,646,144; see also EP0532456B1
	claims
EP0541486A1	US 5,264,431

USAN 10/868,315, 10/199,933 and 10/937,468 are unpublished US patent applications, which will not publish prior to US grant. The Examiner is respectfully requested to consider these applications.

Authorization is given to charge the fee due under 37 C.F.R. §1.17(p), and any fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to Deposit Account 19-2570.

Respectfully submitted,

Loretta J. Sauermelch Attorney for Applicants

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Telephone: (610) 270-6854 Facsimile: (610) 270-5073

n:\Loretta\Applications\P32976\SuppIDS a.doc

Sheet 1 of 5.

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office P32976

SERIAL NO. 10/502,233

APPLICANT Daines et al.

FILING DATE July 22, 2004 GROUP 1625

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

		U.S. PATE	NT DOCUMENTS			
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,264,431	11/23/93	Wacker et al.	514	211	11/6/92
	5,310,743	5/10/94	Schilling, et al.	514	311	8/11/92
	5,541,195	7/30/96	Schilling, et al.	514	311	4/4/94
	5,646,144	7/8/97	Schilling, et al.	514	241	6/7/95
	6,403,610B1	6/11/02	Malleron et al.	514	314	9/18/00
	6,602,882B1	8/5/03	Davies et al.	514	300	PCT
						10/11/99
	6,602,884B2	8/5/03	Bacque et al.	514	314	3/13/02
	6,603,005B2	8/5/03	Baque et al.	546	176	11/14/01
	6,803,369B1	10/12/04	Erskine et al.	514	253.06	7/25/01
	6,815,547B2	11/9/04	Bacque et al.	546	174	3/14/03
	6,841,562B2	1/11/05	Bacque et al.	514	314	9/10/03
	6,903,217B2	6/7/05	Bacque et al.	546	180	6/27/03
	6,911,442B1	6/28/05	Davies et al.	514	230.5	PCT 6/13/00
	6,962,917		Davies et al.	514	264.1	PCT 7/25/01
	6,989,447B2	1/24/06	Markwell et al.	546	152	11/24/03
	7,001,913B1	2/21/06	Davies et al.	514	300	PCT 7/17/02
	7,141,564	11/28/06	Brooks et al.	514	248	PCT 5/24/02
	7,186,730	3/6/07	Dartois et al.	514	266.22	PCT 5/24/02
	7,205,408	4/17/07	Davies et al.	514	243	PCT 1/22/02
	2003-0203917A1	10/30/03	Erskine et al.	514	253.06	5/20/03
	(10/441,435)					·
•	2004-0087619A1	5/6/04	Bacque et al.	514	314	9/10/03
	(10/659,164)				·	
	2005-0085494A1 (10/502,234)	04/21/2005	Daines et al.	514	266.22	PCT 1/27/03

2006-0014749A1	1/19/06	Davies et al.	514	249	9/2/05
(11/219,148)					
2006-0040925A1	2/23/06	Davies et al.	514	222.8	PCT 7/23/03
 (10/522,058)					
2006-0040949A1	2/23/06	Surivet et al.	514	253.04	PCT 10/9/03
(10/529,986)					
2006-0041123A1	2/23/06	Axten et al.	544	48	PCT
(10/538,931)					12/17/03
2006-0058287A1	3/16/06	Axten et al.	514	224.2	PCT 6/25/03
(10/518,655)					
2006-0116512A1	6/1/06	Axten et al.	544	048	PCT 12/3/03
(10/537,034)					
2006-0166977A1	7/27/06	Axten et al.	514	224.2	PCT 11/4/03
(10/533,502)					
 2006-0189604A1	8/24/06	Axten et al.	514	224.2	PCT 6/25/03
(10/518,653)	5.2 5				
2007-0004710A1	1/4/07	Axten et al.	514	224.2	PCT 11/4/03
(10/533,501)	" " " "	, 211011 01 011			
USAN 11/604,045		Brooks et al.		 	11/22/06
 103AN 11/004,043		DIOUKS Et al.			11/22/00

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-	Translation	<u>on</u>
					class	Yes	No
	WO 95/09853	4/13/95	WIPO	,			
	WO 96/15128	5/23/96	WIPO				ļ
	WO 96/38144	12/5/96	WIPO				<u> </u>
	WO 97/03069	01/30/97	WIPO				
	WO 97/17957	5/22/97	WIPO				
	WO 97/45119	12/4/97	WIPO				
	WO 98/02438	01/22/98	WIPO				
	WO 99/37635	7/29/99	WIPO			<u> </u>	
	WO 00/21948	4/20/00	WIPO				
	WO 00/21952	4/20/00	WIPO				
	WO 00/43383	7/27/00	WIPO			. <u></u>	
	WO 00/78748A1	12/28/00	WIPO				
	WO 01/07433A2	2/1/01	WIPO				
	WO 01/25227A2	4/12/01	WIPO			PCT Abstract, family member, EP claims	

T		T	T	· · · · · · · · · · · · · · · · · · ·		
	wo	11/22/01	WIPO			
	01/087839A1		•			
	Rev.					
-	WO 02/24684A1	3/28/02	WIPO			
	WO 02/40474A2	5/23/02	WIPO		PCT Abstract,	
İ					family	
					members	
	WO 02/50040A1	6/27/02	WIPO			
	WO 02/50061A1	6/27/02	WIPO			
	wo	9/19/02	WIPO		PCT Abstract,	
	02/072572A1	i			family	
					members	
	WO 02/96907A1	12/5/02	WIPO			
	wo	2/6/03	WIPO			
	03/010138A2					
	wo	8/7/03	WIPO			
	03/064431A2					
	WO 03/087098	10/23/03	WIPO			
	wo	1/8/04	WIPO			
	04/002490A2					
	wo	1/8/04	WIPO			
	04/002992A1					
	wo	2/19/04	WIPO			
	04/014361A1					
	Corr.					
	wo	3/25/04	WIPO		PCT Abstract,	
	04/024712A1				family member	
	WO	3/25/04	WIPO		PCT Abstract,	
	04/024713A1				family member	
	WO	4/29/04	WIPO		PCT Abstract,	
	04/035569A2	.,20,01			family member	
	WO	5/21/04	WIPO		idning member	
	04/041210A2	5/ 2 1/07				
	WO	6/17/04	WIPO		`	
	04/050036A2	J/1//07	0			
	WO	7/15/04	WIPO	 		
	04/058144A2	1110107	***			
<u> </u>	104/000144A2		L	ll		

WO 04/096982A2	11/11/04	WIPO	
BE772190A1	1/17/72	Belgium	Family
			member
CA 2,004,986A1	6/12/90	Canada	
EP 0238868A2	9/30/87	EPO	
EP 0304493A1	3/1/89	EPO	
EP 0374095A2	6/20/90	EPO	Family
			member,
EP 0532456A1	3/17/93	EPO	Family members, B1 claims
EP 0532456B1	3/29/95	EPO	claims
EP 0541486A1	5/12/93	EPO	Family member
EP 0823429A1	2/11/98	EPO	
EP 1218370B1	12/8/04	EPO	FR2798656 Abstract, claims
GB 1345872	2/6/74	Great Britain	
GB 1537867	1/10/79	Great Britain	
JP 1995179407A	7/18/95	Japan	Machine translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
EXAMINER .	DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether	her or not citation is in conformance with MPEP 609; Draw line through citation if not				
in conformance and not considered. Include co	ppyof this form with next communication to applicant.				

CO-PENDING UNPUBLISHED US PATENT APPLICATIONS

Examiner Initial	Attorney Docket No.	USAN	Inventors	Filing Date	Title	PCT publication
	P51113C	10/868351 (cont of 09/912610, abandoned)	Erskine et a	. 6/15/04	Compounds and Methods for the Treatment of Disease	-
	P51113-1	10/199933, CIP of 09/912610	Erskine et a	. 7/19/02	Compounds and Methods for the Treatment of Disease	-
	P51113-2	10/937468, CIP of 09/912610	Erskine et al	. 9/9/04	Compounds and Methods for the Treatment of Disease	-
EXAMINER:	Initial if citation consi	dered, whether or		ATE CONSIDER		e through citation if not

in conformance and not considered. Include copyof this form with next communication to applicant.

n/loretta/applications/P3s/P32976/supp 1449a.doc